A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury
Study sponsor: Oragenics, Inc. · OGEN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-01-01Estimated
Enrollment · participants40Estimated
Source updated2025-03-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.